Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.

2-Amino-benzo[ d]thiazole was identified as a new scaffold for the development of improved pteridine reductase-1 (PTR1) inhibitors and anti-trypanosomatidic agents. Molecular docking and crystallography guided the design and synthesis of 42 new benzothiazoles. The compounds were assessed for Trypanosoma brucei and Leishmania major PTR1 inhibition and in vitro activity against T. brucei and amastigote Leishmania infantum. We identified several 2-amino-benzo[ d]thiazoles with improved enzymatic activity ( TbPTR1 IC50 = 0.35 μM; LmPTR1 IC50 = 1.9 μM) and low μM antiparasitic activity against T. brucei. The ten most active compounds against TbPTR1 were able to potentiate the antiparasitic activity of methotrexate when evaluated in combination against T. brucei, with a potentiating index between 1.2 and 2.7. The compound library was profiled for early ADME toxicity, and 2-amino- N-benzylbenzo[ d]thiazole-6-carboxamide (4c) was finally identified as a novel potent, safe, and selective anti-trypanocydal agent (EC50 = 7.0 μM). Formulation of 4c with hydroxypropyl-β-cyclodextrin yielded good oral bioavailability, encouraging progression to in vivo studies.

• Publication year

  2019

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2019-03-25

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acs.jmedchem.8b02021PMID 30908048
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.

  2018cited by this paper
• Target product profile: a planning tool for the drug development

  2017cited by this paper
• Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity

  2017cited by this paper
• Comment on The Ecstasy and Agony of Assay Interference Compounds

  2017cited by this paper
• Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.

  2017cited by this paper
• Sleeping sickness can now be cured with pills

  2017cited by this paper
• Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery

  2017cited by this paper
• Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.

  2016cited by this paper
• Hit and lead criteria in drug discovery for infectious diseases of the developing world

  2015cited by this paper
• Drug Discovery for Human African Trypanosomiasis

  2015cited by this paper
• Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development

  2014cited by this paper
• 45 – Human African Trypanosomiasis

  2014cited by this paper
• Drug Discovery for Neglected Diseases: Molecular Target-Based and Phenotypic Approaches

  2013cited by this paper
• Highly Sensitive In Vivo Imaging of Trypanosoma brucei Expressing “Red-Shifted” Luciferase

  2013cited by this paper
• Autoindexing diffraction images with iMosflm

  2013cited by this paper
• Application of a resazurin-based high-throughput screening assay for the identification and progression of new treatments for human African trypanosomiasis.

  2012cited by this paper
• Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes

  2012cited by this paper
• Structure-based selectivity optimization of piperidine-pteridine derivatives as potent Leishmania pteridine reductase inhibitors.

  2012cited by this paper
• Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.

  2011cited by this paper
• Dissecting the Metabolic Roles of Pteridine Reductase 1 in Trypanosoma brucei and Leishmania major*

  2011cited by this paper
• REFMAC5 for the refinement of macromolecular crystal structures

  2011cited by this paper
• iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM

  2011cited by this paper
• Target Validation: Linking Target and Chemical Properties to Desired Product Profile

  2011cited by this paper
• Drug resistance in human African trypanosomiasis.

  2011cited by this paper
• Identification of the binding modes of N-phenylphthalimides inhibiting bacterial thymidylate synthase through X-ray crystallography screening.

  2011cited by this paper
• Human African trypanosomiasis

  2010cited by this paper
• Design, Synthesis and Biological Evaluation of Novel Inhibitors of Trypanosoma brucei Pteridine Reductase 1

  2010cited by this paper
• Molecular replacement with MOLREP.

  2010cited by this paper
• High-resolution structures of Trypanosoma brucei pteridine reductase ligand complexes inform on the placement of new molecular entities in the active site of a potential drug target.

  2010cited by this paper
• Development and validation of a cytochrome c-coupled assay for pteridine reductase 1 and dihydrofolate reductase

  2010cited by this paper
• Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness

  2010cited by this paper
• Features and development of Coot

  2010cited by this paper
• One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening

  2009cited by this paper
• AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

  2009cited by this paper
• Structure-Based Design of Pteridine Reductase Inhibitors Targeting African Sleeping Sickness and the Leishmaniases†

  2009cited by this paper
• Snapshot PK: a rapid rodent in vivo preclinical screening approach.

  2008cited by this paper
• Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7

  2008cited by this paper
• Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

  2008cited by this paper
• High throughput UV method for the estimation of thermodynamic solubility and the determination of the solubility in biorelevant media.

  2008cited by this paper
• Crystallization of soluble proteins in vapor diffusion for x-ray crystallography

  2007cited by this paper
• Scaling and assessment of data quality.

  2006cited by this paper
• Dihydrofolate reductase inhibitors as antibacterial agents.

  2006cited by this paper
• Structure and reactivity of Trypanosoma brucei pteridine reductase: inhibition by the archetypal antifolate methotrexate

  2006cited by this paper
• Chemotherapy of trypanosomiases and leishmaniasis.

  2005cited by this paper
• Coot: model-building tools for molecular graphics.

  2004cited by this paper
• Developments in the CCP4 molecular-graphics project.

  2004cited by this paper
• The trypanosomiases.

  2003cited by this paper
• research papers Acta Crystallographica Section D Biological

  2003cited by this paper
• Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes.

  2002cited by this paper
• Drug-like properties and the causes of poor solubility and poor permeability.

  2000cited by this paper
• Validation of protein models derived from experiment.

  1998cited by this paper
• The Roles of Pteridine Reductase 1 and Dihydrofolate Reductase-Thymidylate Synthase in Pteridine Metabolism in the Protozoan Parasite Leishmania major*

  1997cited by this paper
• VMD: visual molecular dynamics.

  1996cited by this paper
• PTR1: a reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite Leishmania major.

  1994cited by this paper
• The CCP4 suite: programs for protein crystallography.

  1994cited by this paper
• Biological Crystallography an Introduction to Data Reduction: Space-group Determination, Scaling and Intensity Statistics

  year unknowncited by this paper

• Unveiling potent anti-leishmanial agents: a QSAR exploration of diverse chemical scaffolds targeting Leishmania donovani amastigotes

  2025cites this paper
• Syntheses of benzothiazole amidoximes and arylimidamides and evaluation of their ADME and DNA binding properties and activity against Trypanosoma brucei.

  2025cites this paper
• One-Pot, for the Green Preparation of Benzimidazoles and 2,3-Dihydroquinazolin-4(1H)-ones Catalyzed by In2O3 NPs/Glycerol

  2025cites this paper
• Synthetic strategies towards benzothiazole-based compounds of therapeutic potency: experimental, investigational and approved drugs

  2025cites this paper
• Design of 2‑Aminobenzothiazole Derivatives Targeting Trypanosomatid PTR1 by a Multidisciplinary Fragment Hybridization Approach

  2025cites this paper
• Recent Advances in the Application of 2‐Aminobenzothiazole to the Multicomponent Synthesis of Heterocycles

  2024cites this paper
• Privileged small molecules against neglected tropical diseases: A perspective from structure activity relationships.

  2024cites this paper
• Compounds with potentialities as novel chemotherapeutic agents in leishmaniasis at preclinical level.

  2024cites this paper
• Evaluation and discovery of novel benzothiazole derivatives as promising hits against Leishmania infantum

  2024cites this paper
• Semisynthesis of Nocarterphenyl A and Its Analogues.

  2024cites this paper
• Natural Product Identification and Molecular Docking Studies of Leishmania Major Pteridine Reductase Inhibitors

  2024cites this paper
• In Silico Structural Insights and Potential Inhibitor Identification Based on the Benzothiazole Core for Targeting Leishmania major Pteridine Reductase 1

  2024cites this paper
• Synthesis and characterization of a new O,N,O-tridentate ligand and its Cu(I), Cu(II), Ag(I), Cd(II), Zn(II) and Re(II) complexes

  2024cites this paper
• One-pot synthesis of polyhydroquinoline-1,2,3-triazole hybrids in deep eutectic solvent as anti-leishmanial agents and molecular modeling studies

  2023cites this paper
• Structure and dynamics of pteridine reductase 1: the key phenomena relevant to enzyme function and drug design

  2023cites this paper
• Bis-6-amidino-benzothiazole Derivative that Cures Experimental Stage 1 African Trypanosomiasis with a Single Dose

  2023cites this paper
• High-Throughput Phenotypic Screening and Machine Learning Methods Enabled the Selection of Broad-Spectrum Low-Toxicity Antitrypanosomatidic Agents

  2023cites this paper
• The allure of targets for novel drugs

  2023cites this paper
• Crystal structure of the ternary complex of Leishmania major pteridine reductase 1 with the cofactor NADP+/NADPH and the substrate folic acid

  2022cites this paper
• Intramolecular Cascade C–S Bond Formation: A Safe and New Strategy for the Synthesis of Riluzole Analogues Catalyzed by K2S2O8

  2022cites this paper
• Anti-trypanosomatid structure-based drug design – lessons learned from targeting the folate pathway

  2022influential citation
• Elucidating the 3D Structure of a Surface Membrane Antigen from Trypanosoma cruzi as a Serodiagnostic Biomarker of Chagas Disease

  2022cites this paper
• Polycyclic heterocycles by condensation of 1,4-benzoquinone analogs and nucleophiles

  2021cites this paper
• Solid‐Supported Materials‐Based Synthesis of 2‐Substituted Benzothiazoles: Recent Developments and Sanguine Future

  2021cites this paper
• Synthesis, antiproliferative and antitrypanosomal activities, and DNA binding of novel 6-amidino-2-arylbenzothiazoles

  2021cites this paper
• Evidence of Pyrimethamine and Cycloguanil Analogues as Dual Inhibitors of Trypanosoma brucei Pteridine Reductase and Dihydrofolate Reductase

  2021cites this paper
• Phenylbenzothiazole derivatives: effects against a Trypanosoma cruzi infection and toxicological profiles

  2021cites this paper
• p-Trifluoromethyl- and p-pentafluorothio-substituted curcuminoids of the 2,6-di[(E)-benzylidene)]cycloalkanone type: Syntheses and activities against Leishmania major and Toxoplasma gondii parasites.

  2021cites this paper
• Toward New Antileishmanial Compounds: Molecular Targets for Leishmaniasis Treatment

  2021cites this paper
• Exploring biological efficacy of novel benzothiazole linked 2, 5-disubstituted-1, 3, 4-oxadiazole hybrids as efficient α-amylase inhibitors: Synthesis, characterization, inhibition, molecular docking, molecular dynamics and Monte Carlo based QSAR studies

  2021cites this paper
• Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaign.

  2020cites this paper
• High-resolution crystal structure of Trypanosoma brucei pteridine reductase 1 in complex with an innovative tricyclic-based inhibitor.

  2020cites this paper
• The Azoles in Pharmacochemistry: Perspectives on the Synthesis of New Compounds and Chemoinformatic Contributions.

  2019cites this paper
• A Theoretical Study on the Stability, Reactivity and Protonic Affinity of 2-Phenylbenzothiazole Derivatives

  2019cites this paper
• Dear Editor, thank you for reviewing our manuscript “Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaign” submitted for publication in European Journal of Medicinal Chemistry

  2019cites this paper